{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:31:13Z","timestamp":1792218673560,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2021SK51121"],"award-info":[{"award-number":["2021SK51121"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ30430"],"award-info":[{"award-number":["2021JJ30430"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-XD202001-0215"],"award-info":[{"award-number":["Y-XD202001-0215"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.lungcan.2024.107538","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:28:43Z","timestamp":1710764923000},"page":"107538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial"],"prefix":"10.1016","volume":"191","author":[{"given":"Xingxiang","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zemin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoliang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.lungcan.2024.107538_b0005","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107538_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2024.107538_b0015","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.2147\/CMAR.S200126","article-title":"Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma","volume":"11","author":"Zheng","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lungcan.2024.107538_b0020","first-page":"1","article-title":"Immunotherapy for advanced non-small cell lung cancer: a decade of progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107538_b0025","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.7150\/jca.75622","article-title":"A 2022 update on extensive stage small-cell lung cancer (SCLC)","volume":"13","author":"Oronsky","year":"2022","journal-title":"J. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2024.107538_b0030","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107538_b0035","doi-asserted-by":"crossref","first-page":"e004885","DOI":"10.1136\/jitc-2022-004885","article-title":"Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study","volume":"10","author":"Carril-Ajuria","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107538_b0040","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.3747\/co.22.2296","article-title":"An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre","volume":"22","author":"Ma","year":"2015","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107538_b0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3816\/CLC.2010.n.040","article-title":"Second-line treatment for non-small-cell lung cancer: one size does not fit all","volume":"11","author":"Caponi","year":"2010","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107538_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.lungcan.2014.07.006","article-title":"Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study","volume":"85","author":"Auliac","year":"2014","journal-title":"Lung Cancer"},{"issue":"9944","key":"10.1016\/j.lungcan.2024.107538_b0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.107538_b0060","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.2147\/CMAR.S246000","article-title":"Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107538_b0065","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2024.107538_b0070","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.2147\/IJGM.S334436","article-title":"Efficacy and safety of anlotinib monotherapy as third-line therapy for elderly patients with non-small cell lung cancer: a real-world exploratory study","volume":"14","author":"Jiang","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.lungcan.2024.107538_b0075","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.2147\/CMAR.S304838","article-title":"Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer: a real-world study","volume":"13","author":"Zhong","year":"2021","journal-title":"Cancer Manag. Res."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107538_b0080","doi-asserted-by":"crossref","first-page":"e2130","DOI":"10.1002\/onco.13950","article-title":"Anlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: a phase II clinical trial","volume":"26","author":"Xiang","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2024.107538_b0085","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.2147\/CMAR.S249678","article-title":"A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107538_b0090","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107538_b0095","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group","volume":"18","author":"Fossella","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107538_b0100","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)","volume":"118","author":"Han","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107538_b0105","first-page":"5153","article-title":"Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer","volume":"34","author":"Ohyanagi","year":"2014","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.lungcan.2024.107538_b0110","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1177\/0300060519852202","article-title":"A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer","volume":"47","author":"Shimizu","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.lungcan.2024.107538_b0115","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1186\/s12885-015-1756-1","article-title":"Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: thoracic oncology research group (TORG) 1014","volume":"15","author":"Takagi","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2024.107538_b0120","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/cncr.29893","article-title":"Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan oncology group 5910L): an open-label, randomized, phase 2 trial","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2024.107538_b0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clon.2021.12.010","article-title":"Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: results from the ongoing, non-interventional VARGADO study","volume":"34","author":"Grohe","year":"2022","journal-title":"Clin. Oncol. (R Coll Radiol.)"},{"key":"10.1016\/j.lungcan.2024.107538_b0130","doi-asserted-by":"crossref","DOI":"10.1177\/1179554920951358","article-title":"Efficacy of docetaxel plus ramucirumab as palliative third-line therapy following second-line immune-checkpoint-inhibitor treatment in patients with non-small-cell lung cancer stage IV","volume":"14","author":"Brueckl","year":"2020","journal-title":"Clin. Med. Insights Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107538_b0135","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.21037\/jtd.2020.03.54","article-title":"Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial","volume":"12","author":"Song","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107538_b0140","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/1759-7714.12998","article-title":"Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients","volume":"10","author":"Shiono","year":"2019","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107538_b0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2024.107538_b0150","doi-asserted-by":"crossref","unstructured":"T. Leal, D. Berz, I. Rybkin, W.T. Iams, D. Bruno, C. Blakely, et al., MRTX-500: Phase 2 trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy. OncologyPRO, ESMO Congress 2021 2021:Abstract 11910.","DOI":"10.1016\/j.annonc.2021.08.1796"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107538_b0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107538_b0160","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","article-title":"Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107538_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.937924","article-title":"Effective low-dose anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy","volume":"13","author":"Fan","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107538_b0170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2024.107538_b0175","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1200\/JCO.2020.38.15_suppl.9610","article-title":"Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study","volume":"38","author":"Neal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107538_b0180","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1200\/JCO.2021.39.15_suppl.9073","article-title":"A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: big ten cancer Research consortium BTCRC-LUN15-029","volume":"39","author":"Shukla","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"suppl_5","key":"10.1016\/j.lungcan.2024.107538_b0185","first-page":"1308P","article-title":"Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC","volume":"32","author":"Lv","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107538_b0190","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/JCO.2021.39.15_suppl.9033","article-title":"Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: initial efficacy and safety results from VARGADO cohort C","volume":"39","author":"Groh\u00e9","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107538_b0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2020.04.021","article-title":"Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1\/PD-L1 treatment","volume":"144","author":"Tozuka","year":"2020","journal-title":"Lung Cancer"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2024.107538_b0200","doi-asserted-by":"crossref","first-page":"e21055","DOI":"10.1200\/JCO.2021.39.15_suppl.e21055","article-title":"Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): updated results from a phase I\/II study","volume":"39","author":"Fang","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107538_b0205","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1759-7714.12977","article-title":"Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303","volume":"10","author":"Si","year":"2019","journal-title":"Thorac Cancer"},{"issue":"26","key":"10.1016\/j.lungcan.2024.107538_b0210","doi-asserted-by":"crossref","first-page":"e16065","DOI":"10.1097\/MD.0000000000016065","article-title":"Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: a multi center prospective study","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine (Baltimore)"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:06:46Z","timestamp":1777518406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":42,"alternative-id":["S0169500224000710"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107538","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107538"}}